AURA Aura Biosciences, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1501796 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-28.6%
TTM EPS YoY16.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-61.7%
ROA-53.5%
ROIC (approx.)-64.7%
Asset turnover—
Leverage & solvency
Liabilities / assets10.6%
Debt / equity0.00x
Current ratio14.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $24.74M | $30.75M | $27.96M | $21.90M | $22.18M | $22.88M | $23.34M | $22.33M |
| SG&A expense | $10.32M | $17.32M | $6.91M | $5.34M | $5.73M | $5.73M | $5.69M | $5.47M |
| Operating income | -$35.06M | -$48.07M | -$34.87M | -$27.24M | -$27.91M | -$28.61M | -$29.04M | -$27.81M |
| Pretax income | -$32.03M | -$45.61M | -$33.67M | -$25.54M | -$26.10M | -$26.97M | -$27.46M | -$25.81M |
| Income tax | $38,000 | $29,000 | $11,000 | $15,000 | $26,000 | $48,000 | $18,000 | $24,000 |
| Net income | -$32.07M | -$45.64M | -$33.69M | -$25.56M | -$26.13M | -$27.02M | -$27.48M | -$25.83M |
| EBITDA | -$34.76M | -$47.77M | -$34.59M | -$26.96M | -$27.61M | -$28.31M | -$28.74M | -$27.52M |
| EPS (basic) | -0.29 | -0.48 | -0.50 | — | -0.40 | -0.47 | -0.55 | — |
| EPS (diluted) | -0.29 | -0.48 | -0.50 | — | -0.40 | -0.47 | -0.55 | — |
| Weighted avg. shares (diluted) | 111.07M | 94.86M | 67.45M | — | 65.94M | 58.02M | 50.13M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.67M | $67.84M | $84.79M | $59.52M | $47.55M | $107.37M | $38.23M | $31.69M |
| Current assets | $303.10M | $329.03M | $118.50M | $149.74M | $170.12M | $183.96M | $134.52M | $160.62M |
| PP&E, net | $2.02M | $2.20M | $2.47M | $2.62M | $2.63M | $2.86M | $3.11M | $3.21M |
| Total assets | $321.62M | $348.13M | $137.68M | $169.43M | $190.02M | $204.40M | $155.40M | $182.50M |
| Current liabilities | $21.34M | $19.56M | $16.71M | $18.38M | $18.82M | $14.85M | $12.16M | $14.91M |
| Total liabilities | $34.19M | $32.86M | $30.43M | $32.52M | $33.36M | $29.77M | $27.43M | $30.53M |
| Shareholders' equity | $287.43M | $315.27M | $107.25M | $136.91M | $156.67M | $174.63M | $127.97M | $151.97M |
| Shares outstanding | 103.95M | 103.48M | 64.15M | 63.59M | 62.99M | 62.07M | 50.23M | 50.00M |
| Cash flow statement | ||||||||
| Operating cash flow | -$26.44M | -$32.50M | -$29.89M | -$20.47M | -$20.14M | -$20.77M | -$23.36M | -$23.95M |
| Capital expenditure | $80,000 | $21,000 | $102,000 | $176,000 | $45,000 | $39,000 | $187,000 | $299,000 |
| Free cash flow | -$26.52M | -$32.52M | -$30.00M | -$20.64M | -$20.19M | -$20.81M | -$23.54M | -$24.25M |
| Investing cash flow | $114,000 | -$226.03M | $54.90M | $29.82M | -$44.02M | $19.98M | $29.81M | $29.70M |
| Financing cash flow | $206,000 | $241.75M | $300,000 | $2.77M | $4.36M | $69.93M | $96,000 | $543,000 |
| Depreciation & amortization | $300,000 | $300,000 | $274,000 | $272,000 | $300,000 | $300,000 | $291,000 | $291,000 |
| Stock-based compensation | $4.92M | $12.37M | $3.82M | $3.28M | $3.69M | $3.83M | $3.51M | $2.94M |
| Share buybacks | $0 | — | — | — | $0 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.